Zoonotic bacterial infections, such as brucellosis, anthrax, leptospirosis, and bovine tuberculosis, result in a substantial and often underestimated threat to public health and economic stability, particularly in developing countries. These infections, transmitted between animals and humans, are responsible for significant health burdens and financial losses across various sectors, including agriculture, animal health, healthcare systems, trade, and tourism. The economic impact of bacterial zoonotic diseases comprises both direct costs, such as medical treatment, diagnostic testing, and livestock losses, and indirect costs, including reduced productivity, trade restrictions, containment efforts, and foregone income due to illness or death. The livestock sector is particularly affected through decreased milk and meat production, reproductive inefficiencies, and limited market access. In humans, bacterial zoonoses contribute to significant morbidity and mortality, especially in populations with limited access to healthcare. Bacterial zoonotic diseases are often neglected by public health systems, partly due to underreporting and the lack of reliable data. Despite their endemic nature and cumulative impact, they receive less attention compared to viral zoonoses with pandemic potential. Cost-benefit and economic evaluation tools, such as the human capital and willingness-to-pay approaches, help in estimating the financial impact of these diseases to inform policy decisions. Integrating One Health approaches, which bridge human, animal, and environmental health, is essential in controlling these diseases. Addressing these infections requires investment in surveillance, targeted intervention strategies, and policy frameworks that prioritise prevention, particularly in resource-limited settings. Improving data collection, promoting cross-sectoral collaboration, and valuing intangible losses are crucial for reducing their overall impact.